scispace - formally typeset
C

Claude Gervais

Publications -  5
Citations -  2145

Claude Gervais is an academic researcher. The author has contributed to research in topics: Ventilator-associated pneumonia & Pneumonia. The author has an hindex of 3, co-authored 4 publications receiving 2023 citations.

Papers
More filters
Journal ArticleDOI

Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial.

TL;DR: A strategy for setting PEEP aimed at increasing alveolar recruitment while limiting hyperinflation did not significantly reduce mortality, but it did improve lung function and reduced the duration of mechanical ventilation and theduration of organ failure.
Journal ArticleDOI

Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia : A randomized trial

TL;DR: In this paper, the authors evaluated the effect on clinical outcome and antibiotic use of two strategies to diagnose ventilator-associated pneumonia and select initial treatment for this condition and found that the noninvasive management strategy was significantly associated with fewer deaths at 14 days, earlier attenuation of organ dysfunction, and less antibiotic use in patients suspected of having VAP.
Journal Article

Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia

TL;DR: To test the hypothesis that an invasive management strategy is superior to a clinical, noninvasive one in terms of improving clinical outcomes and minimizing antibiotic use, a multicenter, randomized, uncontrolled trial is initiated to compare these strategies in patients suspected of having ventilator-associated pneumonia.
Journal ArticleDOI

Growth-arrest-specific 6 (GAS6) protein in ARDS patients: determination of plasma levels and influence of PEEP setting.

TL;DR: GAS6 plasma level is elevated in ARDS patients and the high-PEEP strategy is associated with a decrease in GAS6 and IL-8 plasma levels at day 3, without significant differences in day 28 mortality between the 2 groups.